Form 4: Foghorn Therapeutics Chief Legal Officer Granted Stock Options

Michael LaCascia, Chief Legal Officer of Foghorn Therapeutics, was granted stock options for 126,000 shares of common stock.

Summary

• Michael LaCascia, the Chief Legal Officer of Foghorn Therapeutics, was granted stock options to purchase 126,000 shares of the company's common stock.
• The exercise price of these options is $4.37 per share.
• The options vest over time, with 25% vesting on January 22, 2026, and the remaining 75% vesting at a rate of 6.25% per quarter thereafter.
• The options expire on January 21, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative sentiment.

Positives

• The granting of stock options aligns the interests of the Chief Legal Officer with the company's long-term performance.
• The vesting schedule encourages continued service and contribution from the executive.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, aligning their interests with shareholders.
• The vesting schedule of 25% after one year and the remainder over subsequent quarters is a typical vesting structure.
• The exercise price of $4.37 is likely based on the current market price of the stock at the time of the grant.

Stakeholder Impact

• The stock option grant may have a slightly dilutive effect on existing shareholders.
• The grant incentivizes the Chief Legal Officer to contribute to the company's success, which benefits all stakeholders.

Key Dates

Keywords

stock options, Foghorn Therapeutics, Michael LaCascia, executive compensation, vesting, equity